Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : H.C. Wainwright & Co.
Deal Size : $6.0 million
Deal Type : Public Offering
Portage Biotech Announces $6.0 Million Registered Direct Offering
Details : The Company intends to use the net proceeds for clinical development of TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : H.C. Wainwright & Co.
Deal Size : $6.0 million
Deal Type : Public Offering
Lead Product(s) : TT-10,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under theagreement, Merck will provide KEYTRUDA for Portage's Phase 1a/1b trial evaluating adenosine 2A receptor antagonist candidate, TT-10 in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 05, 2023
Lead Product(s) : TT-10,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
Details : TT-10 is an orally administered Portage’s adenosine 2A receptor (A2AR) antagonist candidate evaluating in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2023
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
Details : Under the terms of the agreement, Merck will be providing KEYTRUDA for Portage Biotech’s IMPORT-201 trial, a Phase 1/2 study of PORT-2, a liposomal formulation of IMM60, for patients with NSCLC and advanced melanoma (also known as KEYNOTE E69).
Brand Name : IMM60
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Tarus Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Portage Biotech Provides Research and Development Update
Details : TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Tarus Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PORT-6
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Tarus Therapeutics
Deal Size : $53.0 million
Deal Type : Acquisition
Details : As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : $21.0 million
July 06, 2022
Lead Product(s) : PORT-6
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Tarus Therapeutics
Deal Size : $53.0 million
Deal Type : Acquisition
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Intensity Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.
Brand Name : IMM60
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2022
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Intensity Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : STI-001,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Portage, Stimunity and NCI will collaborate with Center for Cancer Research to advance preclinical and clinical development of STING agonists, STI-001 and anti-Receptor for Advanced Glycation End products agents, for possible synergy to enhance the effic...
Brand Name : STI-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : STI-001,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Portage Biotech Provides Update on Clinical-Stage and Development Programs
Details : Clinical trials were initiated in 2021 for both of Portage’s lead invariant natural killer T cell (iNKT) agonist programs, PORT-2 (a liposomal formulation iNKT agonist) and PORT-3 (a nanoparticle coformulation of Portage’s iNKT agonist packaged with ...
Brand Name : IMM60
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2022
Lead Product(s) : IMM60,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Virus Like Particles
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Stimunity
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PORT-5 (STI-001), offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to speci...
Brand Name : PORT-5
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 09, 2022
Lead Product(s) : Virus Like Particles
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Stimunity
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?